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We have previously shown that the thermolabile, cavity-creating p53 cancer mutant Y220C 
can be reactivated by small-molecule stabilizers. In our ongoing efforts to unearth druggable 
variants of the p53 mutome, we have now analyzed the effects of other cancer-associated 
mutations at codon 220 on the structure, stability and dynamics of the p53 DNA-binding 
domain (DBD). We found that the oncogenic Y220H, Y220N and Y220S mutations are also 
highly destabilizing, suggesting that they are largely unfolded under physiological conditions. 
A high-resolution crystal structure of the Y220S mutant DBD revealed a mutation-induced 
surface crevice similar to that of Y220C, whereas the corresponding pocket’s accessibility to 
small molecules was blocked in the structure of the Y220H mutant. Accordingly, a series of 
carbazole-based small molecules, designed for stabilizing the Y220C mutant, also bound to 
and stabilized the folded state of the Y220S mutant, albeit with varying affinities due to 
structural differences in the binding pocket of the two mutants. Some of the compounds also 
bound to and stabilized the Y220N mutant, but not the Y220H mutant. Our data validate the 
Y220S and Y220N mutant as druggable targets and provide a framework for the design of 
Y220S or Y220N-specific compounds as well as compounds with dual Y220C/Y220S 





The tumor suppressor p53 is inactivated by mutation in about half of all tumors, making mutant 
p53 a prime target for cancer therapy.1-3 Most oncogenic p53 mutations are missense mutations 
mapping to its DNA-binding domain (DBD), yet the functional spectrum of these mutations is 
very diverse, depending on the distinct nature of each mutant protein.3-6 Nevertheless, despite 
this functional heterogeneity, mechanistically, the mutations can be broadly divided into DNA-
contact mutations that remove an essential DNA-contact, which prevents p53 from binding to 
its target promoters, and structural mutations. The latter lower the thermostability of the 
intrinsically unstable p53 protein to varying degree, causing it to rapidly unfold and aggregate 
under physiological conditions.7,8 An estimated one third of common p53 cancer mutants are 
temperature-sensitive structural mutants that exhibit a loss of function under physiological 
conditions but retain at least some degree of transcriptional activity when assayed at low 
(permissive) temperatures, where they adopt a wild-type like conformation.4,7,9 It may, 
therefore, be possible to restore the function of this subset of cancer mutants with chemical 
chaperones. The Y220C mutation is an excellent paradigm for this rescue strategy.1 It is the 
ninth most frequent p53 cancer mutation and accounts for an estimated 100,000 new cancer 
cases each year. We have previously shown that this highly destabilizing mutation creates an 
extended surface crevice that can be targeted by stabilizing small molecules (Figure 1).10 Using 
fragment-based screening and structure-based design, we have developed several chemically 
diverse classes of small molecules that bind to this pocket, increase the melting temperature, 
hence stabilize, and slow down the rate of aggregation of the mutant.11-17 Importantly, some of 
those molecules are biologically active in cancer cells with homozygous Y220C mutation and 
induce mutant-specific transcription of a series of p53 target genes,17-19 providing the proof-of-
concept that pharmacological rescue of thermolabile cancer mutants with molecular 
chaperones is a viable and promising strategy. In addition, molecular dynamics simulations 
suggest that it might be possible to target other, transiently open pockets on the DBD 
surface.20,21 Alternative mutant p53 rescue strategies use thiol modifying alkylating agents, 
such as PRIMA-1Met (APR-246)22,23 and sulfonylpyrimidines24, which have been shown to 
selectively kill cancer cells with compromised p53. In addition, metallochaperones have been 
developed for the rescue of the zinc-binding deficient R175H mutant by increasing cellular 
zinc levels.25 These examples illustrate that different reactivation strategies are needed, 
depending on the underlying mechanism of inactivation. No single mutant is found at a 
frequency of >6%, and the ten most frequent and most commonly studied ‘hotspot’ mutants, 
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including the Y220C mutant, together comprise only <25% of all p53 mutations in total.26,27 
Although this translates into a staggering 2.5 million new cancer cases per year, the vast 
majority of cancer patients have non-hotspot mutations with currently largely unknown 
structural and functional impact. 
In our ongoing efforts to structurally characterize the p53 mutome and devise appropriate 
reactivation strategies, we have now analyzed the effects of other frequently occurring 
oncogenic mutations at codon 220 on the structure, stability and dynamics of the p53 DBD. 
These data show that the oncogenic Y220S and Y220N mutations are also highly destabilizing, 
even more so than the Y220C mutant, and, like the Y220C mutant, create a unique extended 
surface crevice that can be specifically targeted by small-molecule stabilizers. 
 
 
RESULTS AND DISCUSSION 
Analysis of cancer mutation frequencies at p53 codon 220 
The TP53 mutation database26 of the International Agency for Research on Cancer lists 402 
cancer cases with a somatic Y220C mutation (Table 1). Based on the total number of reported 
p53 cancer mutations in the database, an overall p53 mutation rate in cancer of about 50%, and 
a total number of 18 million new cancer cases worldwide in 201828, this mutation currently 
accounts for about 125,000 new cancer cases each year, and its tendency is rising. There are 
also three other mutations at codon 220 that occur with an appreciable frequency in the 
database: Y220H, Y220N and Y220S (20, 18, and 17 cases, respectively). As with the Y220C 
mutation, these mutations are found across different types of cancer, including breast, lung and 
liver cancer. Applying the same estimate as for the Y220C mutation, this translates to around 
5,000-6,000 new cancer cases per year worldwide that are caused by each of these mutations. 
Interestingly, the Y220S mutation is also reported in 3 cases of familial cancer, and has been 
associated with oncogenic gain-of-function, including angiogenesis induction and doxorubicin 
resistance.29 Two other mutations, Y220D and Y220F, are found in tumors, albeit very rarely. 
The Y220F mutation is reported only once in the database and is most likely a passenger rather 




Effect of Y220X cancer mutations on the thermostability of the DBD 
We determined the effect of the four most frequent Y220X cancer mutations on the 
thermostability of the DBD by differential scanning fluorimetry (DSF). The mutations were 
introduced in a superstable variant of the p53 DBD (M133L/V203A/N239Y/N268),30,31 which 
has been successfully used previously for structural studies of conformationally unstable p53 
cancer mutants.10,32 All four mutations were highly destabilizing (Table 2). The Y220H and 
Y220C mutations lowered the Tm of the DBD by about 6 ºC and 8 ºC, respectively. The other 
two mutations, Y220S and Y220N, were even more destabilizing, lowering the Tm by ~12 ºC. 
This dramatic stability loss suggests that all four p53-Y220X cancer mutants are largely 
unfolded at physiological conditions in cancer cells, as shown previously for the Y220C 
mutant.18 It will, therefore, be interesting to explore whether the more deleterious effect of the 
Y220S and Y220N mutations on protein stability compared with Y220C and Y220H is also 
associated with a more severe phenotype. 
 
Structures of the Y220S, Y220N and Y220H mutants 
We determined crystal structures of the Y220H and Y220S mutant at a resolution of 1.44 Å 
and 1.50 Å, respectively. The crystals used for structure solution were isomorphous to those 
obtained previously for the Y220C mutant and the stabilized wild-type DBD, and contained 
two molecules in the asymmetric unit. We also collected additional X-ray data for the Y220C 
mutant, extending the resolution from 1.65 Å (PDB entry 2J1X) to 1.24 Å. The overall structure 
of the wild-type DBD and its key functional motifs are conserved in the Y220S and Y220H 
mutant. The Y220S mutant structure, however, also revealed a mutation-induced cavity similar 
to that observed for the Y220C mutation. In both cases, the large-to-small substitution at 
residue 220 connects two pre-existing smaller cavities, resulting in an extended surface crevice. 
A cross-section of the cavity in both mutants is shown in Figure 2, highlighting the conserved 
water network in both mutant structures. Despite the overall similarity in shape, there are 
distinct differences. As a result of the smaller, more polar side chain in the Y220S mutant, the 
subsite-3 region at the bottom of the pocket is slightly deeper and more polar (see Figure 1 for 
the location and numbering of different subpockets). This is reflected in the incorporation of 
an additional, weakly bound water molecule that interacts with the hydroxyl group of Ser220 
(Water W1 in Figure 2A). We have previously shown that the shape of subsite 3 is modulated 
by the conformational state of Cys220.13 In some of the Y220C-ligand complexes, but not in 
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the apo structure, the side chain of Cys220 is flipped, with the sulfhydryl group pointing away 
from the cavity towards a hydrophobic patch formed by the side chains of Leu145, Val157 and 
Leu257, which increases the depth of the binding pocket. Fluctuation between these alternative 
states of the Y220C pocket has also been seen in MD simulations.13 In the case of the Y220S 
mutant, an equivalent flip of the serine side chain would be energetically unfavorable, leaving 
the hydroxyl group in a hydrophobic environment and impeding H-bond formation with 
solvent molecules in the pocket. At the upper rim of the binding pocket, the side chains of 
Thr150 and Pro222 contact each other. This is also observed in some Y220C mutant structures, 
whereas in other structures, Pro222 is further away and the pocket thereby more open, allowing 
access of small-molecule binders.13,15 
In the crystal structure of the Y220H mutant, the imidazole ring of the His220 side chain 
roughly superimposes with the position of the tyrosine aromatic ring in the wild-type structure 
(Figure 2C/D), thereby effectively blocking the binding pocket seen in the other Y220X cancer 
mutant structures. Both imidazole nitrogen atoms form a hydrogen bond with a structural water 
molecule. The partial retention of Tyr220-mediated interactions in the wild type is reflected in 
the less severe stability loss compared with the other Y220X mutants tested.  
For the Y220N mutant, only poorly diffracting crystals were obtained, hence the structure of 
this mutant was modelled with the SWISS-MODEL33 server using the Y220C mutant structure 
as a template. According to this model, the Y220N mutation also creates an extended surface 
crevice, but the center of the pocket is not as deep as in the Y220C and Y220S mutants and 
more polar (Supplemental Figure S1). 
 
Dynamics of the Y220X surface crevice  
We performed molecular dynamics (MD) simulations on the different p53 DBD variants to 
provide insights into the structural plasticity of the mutation-induced binding pocket. The 
stabilized pseudo wild type and the four Y220X mutants of this scaffold were simulated using 
atomistic MD, each for a total of 800 ns (see Methods for details) under physiological 
conditions and in the absence of any stabilizing ligand (only the zinc atom was retained). 
During the simulated time, none of the mutants underwent unfolding, although specific 
fluctuations around the X-ray conformation were observed, revealing the dynamics of the 
systems. The fluctuations of the proteins around their average structure, measured as Cα root-
mean-square fluctuations (RMSF) of residues 97-289, ranked them according to their 
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experimentally determined stability, as seen for other model systems,34 i.e., the lower the 
thermostability of the mutant, the higher the average RMSF in the simulations (Table S1). The 
profile of the RMSF (Supplemental Figure S2) shows enhanced fluctuations of all the Y220X 
mutants around the binding pocket (residue 145-157 and 218-232) compared with the wild 
type, which was expected, given that they lack the Tyr side chain that holds the S3/S4 and 
S7/S8 loops together. The distribution of the distances between the Cδ atoms of Pro151 and 
Pro223 (d1) and between the Cα atom of Pro153 and the Cγ atom of Pro222 (d2), which line 
the pocket, are bimodal for the mutants (but not for the wild type), hinting at the presence of 
open and closed conformations of the pocket in the Y220X mutants (Figure 3). The first 
distance is a measure for the opening/collapse of the central part of the pocket, whereas the 
second distance describes the expanse of subsite 2. The time series of these distances shows 
that open and collapsed conformations are visited repeatedly during the simulations 
(Supplemental Figures S3 and S4). Cluster analysis of the side chains of the residues around 
the pocket (109, 145-157, 218-232, 257) was used to extract representative conformations of 
the open and collapsed state of the central cavity. In the closed state, as shown for the Y220S 
mutant (Figure 3A), Pro153 collapses into the pocket and packs against the side chain of 
Val147 and Pro151 on the other side of the pocket. Y220H, the most thermostable of the four 
Y220X mutants, which incidentally also has the smallest pocket, had the smallest population 
of this state. In the Y220H simulations, collapse of Pro223 into the pocket is linked to a 
displacement of the His220 side chain, which swings out of the pocket, thereby facilitating its 
collapse (Figure 3B). Subsite 2 was generally less prone to collapse than the central pocket in 
the simulations. There was also an interesting difference in the coupling between the two 
subsites in the various mutants. An open state of the central pocket in the Y220S and Y220C 
mutants was generally linked to an open state of subsite 2, but collapse of the central pocket 
did not necessitate the collapse of the subsite-2 region. In contrast, the state of both sub-pockets 
is coupled in the Y220H mutant, where displacement of His220 favors the coordinated collapse 
of both subsites (Figure 3B and Supplemental Figure S5). 
 
Carbazole-based Y220C binders also bind to the Y220S and Y220N mutant 
Given the similarity of the mutation-induced surface crevice in the structures of the Y220C and 
Y220S mutants, we speculated that the molecules we had previously designed for rescuing the 
function of the Y220C mutant might also bind to the Y220S mutant and stabilize it. We 
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therefore tested a selection of our carbazole-based lead structures by DSF thermal shift assays 
and determined the binding constant, Kd, of a few selected compounds by isothermal 
calorimetry (ITC) (Table 3). All Y220C binders tested also stabilized the Y220S mutant, albeit 
to a different extent. Generally, compounds with a larger subsite-2 moiety had a much smaller 
stabilizing effect on the Y220S than on the Y220C mutant at a given concentration, with a 
notable exception being PK9322 and PK9323, which stabilized both mutants equally well. 
Both compounds contain a thiazole moiety that can potentially form a hydrogen bond with 
Ser220. In contrast, compounds with a trifluoroethyl anchor and lacking extensive subsite-2 
extensions had a more stabilizing effect on Y220S than on Y220C. The highest 
thermostabilization among all compounds tested was observed for PK9301, which increased 
the Tm of the Y220S mutant by more than 5 ºC, higher than any stability increase observed for 
the Y220C mutant to date. PK9301 bound to Y220S with a Kd of 4 M (Supplemental Figure 
S6), a slightly higher affinity than determined previously for the Y220C mutant (Kd = 6 M). 
The preference of Y220S for a trifluorylated ethyl anchor was even more pronounced in the 
absence of a subsite-2 targeting moiety. PK9255 bound about 2 times more tightly to the Y220S 
mutant (Kd = 16 M vs Kd = 28 M for Y220C). When comparing the compound-induced 
thermal shifts for the two mutants, one has to take into consideration that the Y220S mutation 
has a higher destabilizing effect than the Y220C mutation (Tm of 12 vs 8 ºC). The potential 
stability gains from optimally targeting the Y220S (and also Y220N) pocket are therefore 
expected to be higher than from targeting the Y220C pocket. 
We also tested a few representative carbazoles against the Y220N and Y220H mutant (Table 
4). Intriguingly, PK9255 also stabilized the Y220N mutant by 1.3 °C and bound with a Kd of 
40 M as measured by ITC (Supplemental Figure S7). Larger compounds with a subsite-2 
extension had no additional stabilizing effects and were in one case actually less effective in 
stabilizing Y220N than PK9255, clearly indicating significant differences in the binding mode 
and/or the architecture of the Y220N pocket. PK9255 had no significant stabilizing effect on 
the Y220H mutant, consistent with the crystal structure of the mutant showing that the histidine 
side chain effectively blocks the center of the binding pocket. These data establish that the 
mutation-induced pocket in the Y220N mutant is also druggable but requires a different design 





Binding modes of carbazole-based Y220S mutant stabilizers 
To provide a rationale for the observed binding affinities, we determined crystal structures of 
the Y220S mutant in complex with the best stabilizers, PK9301 and PK9323, as well as the 
structure of the Y220C mutant with PK9323. The resolution of the structures ranged from 1.4 
Å to 1.8 Å, and there was clear electron density for the bound ligand in each case. The overall 
binding mode of PK9323 in the Y220S mutant resembles closely that observed for other 
carbazoles bound to the Y220C mutant (Figure 4A/B). The carbazole ring system is flanked 
on one side by Val147, Thr150 and Pro151, and on the other side by Pro222, Pro223 and 
Thr230. The secondary amine forms a hydrogen bond with the backbone oxygen of Asp228, 
and the ethyl anchor forms hydrophobic interactions in the subsite-3 region at the bottom of 
the binding pocket. The subsite-2 thiazole moiety shows good shape complementarity with this 
subpocket, with the sulfur atom facing Pro153. Importantly, the thiazole nitrogen forms a 
hydrogen bond with the Ser220 hydroxyl (2.9 Å distance), which explains the preference of 
the Y220S mutant for thiazole-substituted carbazoles over other subsite-2 targeting moieties 
(Table 3). Compared with the structure of the Y220C-PK9323 complex, the overall scaffold is 
shifted slightly toward subsite 2 in the Y220S mutant, and the thiazole ring shows a stronger 
deviation from coplanarity with the carbazole ring system to accommodate the binding pocket 
(average dihedral angle of 14° vs 5°). 
Relative to its orientation in most Y220C complexes, the PK9301 carbazole scaffold is shifted 
slightly towards subsite 2, with the bromine substituent reaching into this subsite, where it 
forms extensive hydrophobic interactions (Figure 4C/D). In the subsite-3 region at the bottom 
of the binding pocket, two fluorine atoms of the trifluoroethyl anchor form a weak hydrogen 
bond with the Ser220 hydroxyl group each (distance of 3.0 and 3.1 Å, respectively), and one 
strongly polarized proton next to the trifluoromethyl group interacts with the hydroxyl oxygen 
atom via weak hydrogen bonding (C…O distance = 3.3 Å). These interactions rationalize why 
a trifluoroethyl anchor is strongly favored over an ethyl anchor (cf. Table 3). The third fluorine 
atom points toward the backbone carbonyls of Leu145 and Trp146, as seen for the Y220C 
mutant, where it forms orthogonal multipolar interactions. The F…O=C distance is 3.9 and 4.2 
Å, respectively, which is slightly larger than the typical interaction distance (3.0–3.7 Å),35 
indicating that the trifluoroethyl group prefers to interact with the Ser220 side chain. Instead 
of directly interacting with the Asp228 backbone, as seen for PK9323, the secondary 
methylamine group forms a hydrogen bond with the backbone oxygen of Val147 and a number 
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of water-mediated contacts with the protein, for example, with the Thr150 side chain at the 
entrance of the pocket.  
Taken together, the analysis of the ligand binding modes in the Y220S and Y220C mutant and 
the SAR (Table 3) provide a framework for the design of binders with dual Y220C/Y220S 
specificity. 
 
Reduced dynamics of the Y220C and Y220S mutant proteins upon ligand binding 
We performed additional MD simulations on the Y220C/S-ligand structures described above 
(Y220S-PK9301, Y220S-PK9323 and Y220C-PK9323) to gain insights into the effect of 
ligand binding on the dynamics of the mutant proteins. After aligning the protein backbone of 
all trajectory frames to the initial conformation, the all-atom RMSD of the ligand with respect 
to its initial conformation was calculated. These values fluctuated around an average of 2.1 Å 
for the two PK9323 complexes and 1.8 Å for the Y220S-PK9301 complex, with a standard 
deviation of 0.5 Å in all three cases. The small fluctuations around the initial structure indicate 
that the protein-ligand complexes were very stable during the timescale of the simulations. 
Ligand binding stabilized the protein in all three simulations, resulting in drastically reduced 
average RMSFs compared with the unbound mutant structure (Table S1). For the Y220C-
PK9323 complex, the overall RMSF was actually lower than that of the wild-type DBD. For 
the Y220S-ligand complexes studied, PK9323 and PK9301, reduction of the average RMSF 
correlated with the affinity and effect on thermostability of the compound, i.e., the more potent 
binder and stabilizer PK9301 induced a stronger decrease of the average RMSF than PK9323 
(cf. Tables 3 and S1). Analysis of the RMSF for individual residues also provided interesting 
information (Supplemental Figure S8). The elevated RMSFs for residues on both sides of the 
mutation-induced binding pocket in the MD simulations of the native Y220C and Y220S 
mutant, i.e., residues 147-153 and around residue 220, went back to wild-type levels upon 
ligand binding, indicating stabilization of the local structure of the pocket region. This local 
stabilization was also reflected in the distances of specific pocket parameters describing the 
state of the central cavity (d1) and subsite 2 (d2), i.e., the distances between the Cδ atoms of 
Pro151 and Pro223 (d1) and between the Cα atom of Pro153 and the Cγ atom of Pro222 (d2) 
(see Figure 3). In the MD simulations of the native mutants, there was a bimodal distribution 
of both pocket parameters, corresponding to open and collapsed states of the pocket. In 
contrast, in both the Y220C and Y220S ligand complexes, there was a reversal to a unimodal 
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distribution, as seen for the wild type, and the distances stayed close to the values in the starting 
structure throughout the simulation (Figures S3 and S4). Comparison of the subsite-2 
parameter, d2, in the two Y220S-ligand complex simulations also shows that there is a slight 
narrowing of subsite 2 with PK9301, which has a smaller subsite-2 targeting moiety than 
PK9323 (bromine vs thiazole). Especially in the Y220S-ligand complexes, a number of long-
range effects were also observed, resulting in reduced structural fluctuations in the distant L2 
and L3 loops in the ligand-bound mutant (Figure S8). 
Overall, the MD simulations support the notion that our molecules act as a molecular glue that 
stabilizes both the local and global structure, reducing conformational sampling and increasing 
the thermostability of the Y220X mutant proteins. 
 
CONCLUSION & OUTLOOK 
We have shown that the four most common oncogenic Y220X mutations drastically impair the 
thermostability of the p53 DBD. Crystal structures and MD simulations further revealed that 
three of them result in the formation of an extended surface crevice with unique properties. 
Importantly, our data establish that both the Y220S and Y220N mutants, in addition to the 
Y220C mutant, are druggable targets for restoring the function of those mutants in tumors with 
small-molecule stabilizers. The structural and biophysical data presented here provide a 
framework for the development of both specific and dual Y220S/Y220C stabilizers, whereas 
the Y220N mutant most likely requires a different design strategy for achieving the required 
potency. In addition, MD simulations provided complementary structural and dynamical 
information that can inform the rational design and optimization of Y220X ligands. Systematic 
structural studies on other p53 cancer mutants, combined with virtual and fragment screening 
approaches, are likely to unearth more oncogenic variants with druggable pockets. These 
studies should further expand the druggable p53 mutome for cancer therapy and aid the 
development of new personalized cancer drugs.  
Shortly before submission of this manuscript, a docking study with our initial Y220C stabilizer 
PK083 was published, suggesting that it may preferentially bind to the Y220S mutant, although 





MATERIALS AND METHODS 
 
Compound synthesis 
Synthesis routes of chemical compounds, except PK9301, have been described elsewhere.17 1-
(7-Bromo-9-(2,2,2-trifluoroethyl)-9H-carbazol-3-yl)-N-methylmethanamine (PK9301). To a 
solution of 7-bromo-9H-carbazole-3-carbaldehyde (200 mg, 0.72 mmol), in anhydrous DMF 
(3 mL) was added caesium carbonate (475 mg, 1.45 mmol) and 2,2,2-trifluoroethyl-p-
toluenesulfonate (356 mg, 1.45 mmol). The reaction mixture was irradiated in the microwave 
at 150 ºC for 30 minutes. The crude product was purified by chromatography on silica gel using 
EtOAc/hexane 1/4 to 1/1 over 20 minutes. 7-Bromo-9-(2,2,2-trifluoroethyl)-9H-carbazole-3-
carbaldehyde was isolated as a white solid, yield 52% (134 mg, 0.37 mmol). 1H NMR (500 
MHz, DMSO-d6) δ 10.06 (s, 1H, CHO), 8.78 (s, 1H, ar CH), 8.25 (d, J = 8.5 Hz, 1H, ar CH), 
8.14 (s, 1H, ar CH), 8.05 (d, J = 8.5 Hz, 1H, ar CH), 7.91 (d, J = 8.5 Hz, 1H, ar CH), 7.49 (d, 
J = 8.5 Hz, 1H, ar CH), 5.55 (q, 3J FH = 9.2 Hz, 2H, CH2) ppm. 13C NMR (126 MHz, DMSO-
d6) δ 192.3, 144.3, 142.3, 130.2, 127.9, 125.3 (q, 1JFC = 281.7 Hz), 124.5, 124.2, 123.0, 122.7, 
122.1, 120.4, 113.9, 11.2, 44.1 (q, 2JFC = 33.0 Hz) ppm. MS-EI (m/z) found 355 [M]+, calcd 
355. 
To a solution of the latter compound (85 mg, 0.24 mmol), used as such, in anhydrous 
EtOH/DCM (2 mL) was added methylamine hydrochloride (32 mg, 0.48 mmol), triethylamine 
(49 μL, 0.35 mmol), and titanium (IV) isopropoxide (141 μL, 0.48 mmol). The resulting 
solution was stirred at RT for 18 h before the addition of sodium borohydride (18 mg, 0.48 
mmol). The solution was stirred at RT for 8 h before pouring into 2 M aqueous ammonia (10 
mL). The suspension was filtered through Celite, and to the filtrate was added H2O. Crude 
product was extracted with DCM, dried over anhydrous K2CO3. The suspension was filtered, 
and the filtrate was concentrated in vacuo to yield crude product that was purified by 
chromatography on silica gel using DCM/MeOH 9:1 as an eluent to yield the product as a 
colorless solid, yield 36% (32 mg, 0.08 mmol). 1H NMR (500 MHz, DMSO-d6) δ 8.32 (s, 1H, 
ar CH), 8.08 (s, 1H, ar CH), 8.05 (d, J = 8.5 Hz, 1H, ar CH), 7.80 (d, J = 8.5 Hz, 1H, ar CH), 
7.69 (d, J = 8.5 Hz, 1H, ar CH), 7.44 (d, J = 8.5 Hz, 1H, ar CH), 5.49 (q, 3J FH= 9.0 Hz, 2H, 
CH2), 4.23 (s, 2H, CH2), 2.53 (s, 3H, CH3) ppm. 13C NMR (126 MHz, DMSO-d6) δ 141.9, 
140.9, 128.9, 124.5, 123.7, 123.4 (q, 1JFC = 285.3 Hz), 122.8, 122.4, 122.3, 121.8, 119.8, 113.6, 
110.8, 51.9, 43.9 (q, 2JFC = 33.2 Hz), 32.2 ppm. HRMS-ESI (m/z) found 339.9470 [M]+, calcd 
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339.9943 for [C15H10BrF3N]+ (loss of NHMe). LC-MS purity = 97% (UV), ret. time = 12.55 
min. 
 
Differential scanning fluorimetry 
Melting temperatures of the p53 mutants were determined by differential scanning fluorimetry 
(DSF) using the dye SYPRO Orange (Invitrogen), which quantitatively binds to hydrophobic 
protein patches that become exposed upon thermal unfolding. Real-time melt analyses were 
performed using either an Agilent MX3005P (heating rate of 270K/h excitation/emission filters 
= 492/610 nm; Tables 2 and 4) or a Corbett Rotor-Gene 6000 real-time qPCR thermocycler 
(heating rate of 180 K/h, excitation/emission filters = 460/510 nm; Table 3). Tm measurements 
were performed with 8 μM p53 protein and 5-10×SYPRO Orange (Life Technologies) in a 25 
mM KPi (pH 7.2), 150 mM NaCl, and 1 mM TCEP assay buffer. For measurements of 
compound-induced Tm shifts (ΔTm), the assay buffer additionally contained 5% DMSO (v/v), 
with either 250 M ligand or no ligand (control). ΔTm values were calculated as ΔTm = Tm 
(protein + compound) − Tm (protein). Native melting curves were measured in quadruplicate, 
and compound-induced thermal shifts in triplicate or higher. Mean values ± SEM are given. 
 
Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) experiments for the Y220C and Y220S mutants were 
performed using a MicroCal (Amherst) iTC200 calorimeter as described.14 Briefly, the cell unit 
contained 30-50 μM protein in a 25 mM KPi (pH 7.2), 150 mM NaCl, 1 mM TCEP, and 5% 
(v/v) DMSO assay buffer. The syringe contained 0.5−2 mM compound in the same buffer, 
using injection steps of 2 μL at a rate of 0.5 μL/s (initial injection: 0.5 μL) and 120 s spacing. 
For the poorly soluble PK9223, a reverse titration was performed. Data analysis was performed 
using the MicroCal Origin software. ITC measurements for the Y220N mutant were carried 
out with the same buffers as above but using a Nano ITC microcalorimeter (TA Instruments) 
and injection steps of 8 μL, at a rate of 0.5 μL/s, and 200 s spacing. Data were processed using 
the NanoAnalyze™ software (Version 3.5.0) supplied with the instrument. All measurements 
were performed at 20 °C. 
 
Protein expression and purification 
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Protein expression and purification was performed following published protocols.11 Briefly, 
we used a pET24a-based expression vector encoding a fusion protein with an N-terminal 6xHis 
tag, followed by the lipoyl domain of the dihydrolipoamide acetyltransferase from Bacillus 
stearothermophilus, a TEV protease cleavage site, and the mutant p53 DBD (residues 94-312) 
of interest. Point mutations in the p53 DBD were introduced using the QuickChange site-
directed mutagenesis kit (Agilent). All mutations were introduced into a stabilized quadruple 
mutant variant of the human DBD (M133L/V203A/N239Y/N268D) that we used successfully 
for studying the effects of destabilizing p53 mutations in the past.10,37 The recombinant proteins 
were expressed in E. coli C41. Cells harbouring the expression vector were grown in 2TY 
medium at 37 °C up to an OD600 = 0.6-0.8. At this point, the temperature was lowered to 20 
ºC, and protein expression was induced by adding IPTG (0.5 mM) and the cells were further 
supplemented with 0.1 mM zinc chloride. Cells were grown overnight and then broken by 
either sonication or French press. The p53 mutants were purified using a nickel column, 
followed by TEV protease cleavage overnight and a second purification step on a heparin 
column. After an additional gel filtration chromatography step, the mutants were concentrated 
to 6 mg/ml, flash frozen in liquid nitrogen and stored at -80 ºC. 
 
Protein crystallization and structure determination 
Crystals of the Y220C, Y220S and Y220H mutant were grown at 20 °C using the sitting drop 
vapor diffusion technique by mixing equal amount of protein solution (6 mg/ml mutant protein 
in 25 mM phosphate buffer, pH.7.2, 150 mM NaCl, and 5 mM DTT) and reservoir buffer (19% 
(w/v) polyethylene glycol 4000, 100 mM HEPES, pH 7.2, and 5 mM DTT). Rod shaped 
crystals grew within a few days. Crystals of the Y220S-PK9323 complex were grown under 
the same condition but with the crystallization buffer supplemented with 2 mM PK9323. All 
crystals were cryoprotected with mother liquor supplemented with 20% glycerol and flash 
frozen in liquid nitrogen. For additional soaking experiments, crystals of the Y220S mutant 
were soaked for 60 min in a saturated solution of PK9301 in cryoprotection buffer prior to flash 
freezing, and crystals of the Y220C mutant were soaked for 3.5 h with a saturated solution of 
PK9323 in the same cryoprotection buffer as above prior to flash freezing. X-ray data sets were 
collected at 100 K at beamline I03 of the Diamond Light Source, Oxford, UK, and beamline 
X06SA of the Swiss Light Source, Villigen, Switzerland. The diffraction data were integrated 
with the program XDS38 and scaled with either SCALA39 or AIMLESS40, which are both 
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implemented in the CCP4 package.41 The structures were solved by difference Fourier analysis 
in PHENIX42 using PDB entry 2J1X as a starting model with initial rigid body refinement. 
Structure refinement was performed using iterative cycles of manual model building in 
COOT43 and refinement in PHENIX. Dictionary files for the PK9301 and PK9323 ligands were 
generated using the Grade Web Server (http://grade.globalphasing.org). In the structure of the 
Y220S complex with the brominated ligand PK9301, there was significant negative difference 
electron density at the bromine after refinement, as observed previously for a similar compound 
with the Y220C mutant,17 suggesting a partial, radiation-induced loss of the bromine atom. 
Data collection and refinement statistics are listed in Table 5. Structural figures were prepared 
using PyMOL (www.pymol.org). 
 
Molecular Dynamics Simulations 
Molecular dynamics (MD) simulations were setup for the DBD of stabilized pseudo wild-type 
p53 and the four Y220X mutants of this scaffold. Starting models were PDB entries 1UOL and 
the mutant crystal structures determined in this study (chain A). For the Y220N mutant, a model 
using SWISS-MODEL33 with the Y220C mutant structure (PDB ID: 2J1X) as a template was 
used. Ligands (e.g. buffer molecules, glycerol from the crystallization conditions) were 
removed from the calculations. The structures of the mutants were solvated in truncated 
octahedron simulation boxes with walls at least 1.2 nm away from the protein. The TIP3P44 
model was used for the explicit simulation of water molecules. The system was neutralized and 
taken to physiological ion concentration (0.15 M) by changing some water molecules into 
sodium and chlorine ions. Simulations were carried out with the CHARMM36m force field45 
and the program GROMACS.201846. The zinc ion and the coordinating cysteine/histidine 
residues were modeled according to Budiman et al. (2007) and Godwin et al. (2017).47,48 This 
resulted in systems comprising between 35570 and 42173 atoms. The temperature of the 
system was kept constant at 300 K using a Nosé-Hoover thermostat49,50 with τt=1ps and the 
pressure was kept constant at 1 bar with the Parrinello-Rahman algorithm51 with τp=1ps. Direct 
non-bonded interactions were cut-off at 1.2 nm with a switch function on Van-der-Waals 
interactions starting at 1.0 nm. Long-range electrostatic interactions were computed using 
sPME.52 The covalent bonds with hydrogen atoms were constrained with the LINCS 
algorithm53, and the integration time step was set to 2 fs. The systems were minimized for max 
50000 steps, then equilibrated in the NVT ensemble for 1 ns with positional restraints on the 
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positions of the heavy atoms of the protein. Then, they were further equilibrated for 1 ns in the 
NPT ensemble with no restraints.  Four production runs were started for each mutant. Each run 
was 200 ns long. The resulting trajectories were analyzed using VMD54 and WORDOM55.  
Ligands were modeled using the CHARMM general force field (CGenFF56 4.0, program 
version 2.2.0, https://cgenff.umaryland.edu) based on their similarity to previously 
parametrized compounds. The very small deviation observed along the MD simulations 
(maximal average RMSD of 2.1 Å over all atoms including hydrogens) of the ligands from 
their position in the crystallographic structure (after addition and minimization of the 
hydrogens) confirmed that the parametrization was appropriate. 
 
Accession Codes: Coordinates and structure factors of the p53-Y220X mutant structures have 
been deposited in the Protein Data Bank (PDB). Accession codes: 6SHZ, 6SI0, 6SI1, 6SI2, 





This material is available free of charge via the internet at http://pubs.acs.org. 
Model of the mutation-induced cavity in the p53-Y220N mutant; RMSFs of C atoms in MD 
simulations of p53-Y220X mutant DBDs and correlation between average RMSFs and protein 
thermostability; selected pocket parameters as a function of time over all MD simulations of 
Y220X mutant DBDs; correlation between subsite 2 and the central cavity in the MD 
simulations of the Y220S, Y220C and Y220H mutant; ITC curve for binding of PK9301 to 
mutant Y220S and binding of PK9255 to mutant Y220N. 
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Table 1. Frequency of p53 cancer mutations at codon 220 
Mutation Somatic counta Germline counta 
Y220C 402 17 
Y220H 20 0 
Y220N 18 0 
Y220S 17 3 
Y220D 4 0 
Y220F 1 0 
aNumber of cases in release R20 of the TP53 mutation database of the International Agency 











WT residue 51.5 ± 0.1 - 
Y220H 45.1 ± 0.1 -6.4 
Y220C 43.7 ± 0.1 -7.8 
Y220N 39.9 ± 0.2 -11.6 
Y220S 39.4 ± 0.2 -12.1 
aMelting temperatures of Y220X mutants were measured in the framework of a stabilized 
quadruple mutant DBD (M133L/V203A/N239Y/N268D). The Tm of the wild-type DBD is 
~45 °C.32,57 Quadruplicate measurements, mean ± SEM is given. 





Table 3. Thermostabilization and dissociation constants of carbazole-based Y220S and 
Y220C binders 
 
   Y220S mutant Y220C mutant 
Compound R1 R2 Tm (°C)a Kd (µM) Tm (°C)a Kd (µM) 
PK083 CH2CH3 H 0.7 ± 0.1 - 1.0 ± 0.1 125 ± 10 b 
PK9284 CH2CH3 Br 1.8 ± 0.1 - 2.4 ± 0.1 14 ± 2 b 
PK9295 CH2CH3 
 
0.9 ± 0.0 - 1.2 ± 0.1 62 ± 7 b 
PK9318 CH2CH3 
 
2.1 ± 0.0 - 4.4 ± 0.1 2.6 ± 0.4 b 
PK9320 CH2CH3 
 
1.8 ± 0.1 - 3.4 ± 0.0 4.1± 0.2 b 
PK9322 CH2CH3 
 
3.0 ± 0.0 - 3.4 ± 0.0 8.3 ± 2.6 b 
PK9323 CH2CH3 
 
3.7 ± 0.3 5.9 ± 1.3 3.1 ± 0.1 5.3 ± 1.4 b 
PK9424 CH2CH3 
 
1.2 ± 0.1 - 2.3 ± 0.1 - 
PK9327 CH2CH3 
 
1.2 ± 0.0 - 3.7 ± 0.2 - 
PK9328 CH2CH3 
 
1.5 ± 0.1 - 3.7 ± 0.0 1.7 ± 0.2 b 
PK9331 CH2CH3 
 
1.1 ± 0.1 - 2.1 ± 0.1 - 
PK9255 CH2CF3 H 3.2 ± 0.0 16 ± 2 1.7 ± 0.1 28 c 
PK9301 CH2CF3 Br 5.1 ± 0.1 4.0 ± 1.0 3.5 ± 0.1 6.0 ± 0.3 
a Measured at a compound concentration of 250 µM. Mean values of quadruplicate measurements ± 
SEM are shown. 
b Data taken from Bauer et al. (2019)17. 





Table 4: Differential stabilization of Y220X mutants 
 
    Tm (°C)a 
Cpd. R1 R2 R3 WT Y220C Y220S Y220N Y220H 
PK9255 CH2CF3 H H 0.0 ± 0.1 1.7 ± 0.1 3.2 ± 0.0 1.4 ± 0.1 0.2 ± 0.1 
PK9285 CH2CH3 Br CH3 -0.2 ± 0.1 2.0 ± 0.0 2.1 ± 0.1 1.4 ± 0.1 0.2 ± 0.0 
PK9321 CH2CH3 
 
H 0.2 ± 0.1 3.1 ± 0.1 2.1 ± 0.1 1.4 ± 0.1 0.7 ± 0.1 
PK9323 CH2CH3 
 
H -0.4 ± 0.2 3.1 ± 0.1 3.7 ± 0.3 0.7 ± 0.1 -0.3 ± 0.1 




Table 5. X-ray data collection and refinement statistics 
Structure Y220C Y220C-9323 Y220H Y220S Y220S-9301 Y220S-9323 
Data Collection       
Space Group P212121 P212121 P212121 P212121 P212121 P212121 
a (Å) 65.18 64.88 64.76 65.06 64.98 65.22 
b (Å) 71.15 71.14 70.77 71.22 71.30 71.19 
c (Å) 105.04 104.74 104.88 105.40 105.72 105.16 
Molecules/AU  2 2 2 2 2 2 












Unique reflections 135,992 72,947 86,307 78,532 96,281 45,643 
Completeness (%)a 98.0 (96.2) 99.0 (97.7) 98.5 (97.7) 99.4 (99.4) 99.3 (99.4) 99.1 (99.9) 
Multiplicitya 5.5 (5.5) 4.1 (3.9) 5.5 (5.6) 4.7 (4.6) 4.7 (4.7) 4.3 (4.4) 
Rmerge (%)a 5.3 (58.2) 5.3 (63.6) 8.6 (63.5) 6.0 (52.9) 5.3 (48.4) 8.9 (54.1) 
CC(1/2)a 0.999 (0.887) 0.999 (0.798) 0.995 (0.888) 0.999 (0.875) 0.999 (0.895) 0.996 (0.873) 
Mean I/(I)a 15.6 (3.1) 14.1 (2.5) 9.3 (2.4) 14.5 (2.9) 13.1 (3.0) 8.9 (2.5) 
Refinement        
Rwork, (%)b 15.1 14.3 15.2 14.7 15.1 19.0 
Rfree, (%)b 17.2 17.3 17.8 17.7 17.6 22.4 
No. of atoms       
Proteinc 3171 3100 3131 3082 3117 3064 
Zinc 2 2 2 2 2 2 
Water 513 474 516 474 445 392 
Ligands 14 71 31 18 62 52 
RMSD bonds (Å) 0.005 0.006 0.006 0.005 0.005 0.006 
RMSD angles () 0.8 0.8 0.8 0.8 0.8 0.8 
Mean B (Å2)  18.5 21.0 18.8 22.6 21.5 22.6 
PDB entry 6SHZ 6SI0 6SI1 6SI2 6SI3 6SI4 
aValues in parentheses are for the highest resolution shell.   
bRwork and Rfree = ∑||Fobs| - |Fcalc||/∑|Fobs|, where Rfree was calculated with 5 % of the reflections chosen at random and not 
used in the refinement. 













Figure 1. Mutation-induced surface crevice in the p53 cancer mutant Y220C with bound molecule 
PK083. The mutant protein is shown as a surface representation in two different orientations: cross 
section of the mutation-induced surface crevice and top view. Bound carbazole-based stabilizer PK083 
is shown as a stick model (PDB ID: 2VUK). Specific regions of the pocket that are discussed in this 






























Figure 2. Structures of the Y220X mutants. Molecular surface representation of a cross-section of the 
mutation-induced surface crevice in mutants Y220S (A) and Y220C (B). Water molecules bound inside 
the pocket are shown as small spheres and color-coded according to their crystallographic thermal 
factors (B factors) in a rainbow gradient from blue (B factor = 10 Å2) to red (B factor = 50 Å2). Water-
mediated hydrogen bonds are highlighted with orange dashed lines. Selected side chains in the pocket 
are highlighted as stick models. (C) The equivalent cross-section of the wild-type structure (PDB ID 
1UOL) shows that Tyr220 prevents formation of an extended surface crevice and effectively separates 
two smaller, pre-existing subpockets. (D) In the structure of the Y220H mutant, the histidine side chain 
overlays with the position of the Tyr side chain in the wild type, which also blocks the binding pocket. 






































































































Figure 3. MD simulations of Y220X mutants showing open and closed states of the pocket region. (A) 
Superposition of Cα traces of the crystal structure of the Y220S mutant (green) and three representative 
structures of open and closed states along the trajectory. Selected side chains are shown as stick models. 
Selected distances across the central cavity (d1) and subsite 2 (d2) are highlighted with magenta dashed 
lines. (B) Superposition of Cα traces of the crystal structure of the Y220H mutant (green) and three 
representative structures of open and closed states along the trajectory. The view is the same as in panel 
A. Concerted collapse of the pocket region is associated with His220 swinging out of the pocket. (C) 
Distribution of representative distances shows that the Y220X mutants visit open and closed states 
during the simulations, whereas the wild type stays close to the conformation of the crystal structure. 
The distance between the Cδ atoms of Pro151 and Pro223 (left) is a measure for the width of the central 
cavity, whereas the distance between the Cα atom of Pro153 and the Cγ of Pro222 spans subsite 2. The 
green line indicates the distance in the corresponding crystal structures (chain A), or the starting model 
in case of the Y220N mutant. 
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Figure 4. Structures of the p53-Y220S mutant in complex with PK9301 and PK9323. (A) Molecular 
surface representation of a cross-section of the mutation-induced surface crevice in the Y220S mutant 
with bound PK9323, showing that the thiazole moiety of the ligand forms a hydrogen bond with Ser220. 
(B) Structure of the Y220C-PK9323 complex; same view as for the Y220S-PK9323 complex in (A). 
(C) Structure of the Y220S-PK9301 complex. Key residues in the binding pocket are shown as stick 
models. A structural water molecule interacting with the aminomethyl substituent is shown as a red 
sphere. Ligand-mediated hydrogen bonds are shown as orange dashed lines. (D) Superposition of the 
binding modes of PK9323 in Y220S and Y220C as well as PK9301 in Y220S. The ligands and the 
mutated side chain are shown as stick models. Polar interactions with Ser220 are shown as dashed lines 
in the same color as the corresponding structure. 
